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Abstract

Infantile hemangioma (IH) is the most common tumour of infancy.

The

recommended treatment for IH is a non-selective β-adrenergic receptor antagonist,
propranolol.

Although propranolol is effective in regressing hemangiomas, the

mechanism of its action is poorly understood.

Moreover, some hemangiomas

regrow following cessation of treatment. We have recently shown that IH arise from
multi-potent stem cells. Whether IH stem cells are responsive to propranolol is
unknown and is the focus of this study.

Hemangioma-derived stem cells and

vascular endothelial cells were exposed to propranolol and were assayed for cellular
and molecular alterations. Our studies show that propranolol inhibits the growth of
hemangioma stem cells but does not cause apoptosis. We further show that the
mechanism may involve serotonin receptors in hemangioma stem cells.

These

findings are in contrast to endothelial cells, which exhibit apoptosis potentially
through the action of propranolol on β-adrenergic receptors. This study reveals that
propranolol’s

therapeutic

effect

is

β-adrenergic

receptor-independent

in

hemangioma-derived stem cells.

Keywords:
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Chapter 1
1

Introduction1,2

1.1

Infantile hemangioma

Infantile hemangioma (IH) is the most common vascular tumour of infancy,
affecting one of every 100 newborns [1, 2]. For reasons unknown, IH affects
more females than males, and is also more prevalent in premature and
Caucasian babies [3, 4]. IH is often noticed soon after birth where approximately
80% of these lesions are found in the head and neck regions, but they can be
located elsewhere in the body [5-7]. It has been well-established that IH follows
three developmental phases [8, 9].

The first phase entails expansion of

undifferentiated tumour cells [10, 11]. This proliferating stage is completed by 8
months of age in most cases [11].

In the following involuting phase, these

tumour cells differentiate into atypical vascular endothelial cells (ECs) [12, 13].
Uniquely, IH endothelium exhibits robust expression of glucose transporter-1
(Glut1) [14, 15]. The involuting phase, like the proliferating phase, is a continuum
of cellular and molecular changes with the end result being appearance of
adipocytes and fibrofatty residuum [8, 9, 13]. Most IHs resolve spontaneously
and do not require treatment [16].

However, therapeutic intervention is

necessary in cases where the lesion grows in certain locations and to sizes that
could result in life-threatening complications. An example of such a situation is
the growth of IH in the airway to obstruct the respiratory system [17].

2
1

Parts of this chapter have been published: Kum JJY, Khan ZA. Mechanisms of
propranolol action in infantile hemangioma. Dermato-Endocrinology. 2014; 6:1,
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Research applies the Nature Publishing Group (NPG) author licence policy to
works. Under the license, authors retain ownership of the copyright for their
published contributions. No permission is required from the publisher of the
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1.2

Treatment options for hemangioma

Although many attempts have been made, the treatment guidelines for IH are not
fully established due to differential effects of diverse therapeutic options, the
differences in the location, stage, and size of the tumour, and the age of patients
[16]. Typically, treatment is initiated as soon as possible to avoid unnecessary
disfigurement as hemangioma growth is highly unpredictable.

Hence, many

treatments are introduced during the early proliferative phase of IH. Currently,
laser treatments, β-blockers, surgery and corticosteroids are available for
hemangioma patients [18-21]. Although many treatment options are available,
the therapeutic mechanism of action of the pharmacological treatment options is
poorly understood.

Many studies suggest that treatments target the anti-

angiogenic pathway to reduce the rapid growth of blood vessels during the early
proliferative phase of hemangiomas.
Corticosteroids were once considered to be a standard treatment for
hemangiomas. Unfortunately, high doses of systemic corticosteroid treatment
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over extended periods of time have produced severe side effects including
severe growth retardation, immunosuppression, and inhibition of wound healing
[22, 23].
Propranolol is a synthetic non-selective β-adrenergic receptor (β-ADR)
antagonist, commonly referred to as a β-blocker. It is a commonly used drug for
cardiac complications, such as hypertension and myocardial infarctions. In 2008,
propranolol was accidentally found to be an effective pharmacological alternative
for hemangiomas in two infants [24].

These infants, while receiving

corticosteroids for hemangioma, were also given propranolol to treat cardiac
complications. Upon propranolol treatment, hemangiomas regressed rapidly in
these patients. Since then, propranolol has been used world-wide as the firstline treatment option for hemangioma patients. Many studies have compared
corticosteroids and propranolol use for hemangiomas, and it has been shown
that propranolol is more effective with minimal side effects when compared to
corticosteroid use [24, 25].
Despite remarkable efficacy of propranolol [26], there are some adverse effects,
which include sleep disturbances, acrocyanosis, hypotension, and hypoglycemia
[25, 27, 28].

There are also reports of IH regrowth following cessation of

treatment in as many as 20% of the cases [29, 30].

Therefore, greater

understanding of the potential mechanisms underlying the therapeutic effect is
needed to develop better and safer treatment options. Many mechanisms have
been proposed, though only tested in culture studies, to explain the therapeutic
mechanism of propranolol in treating IH.

Theories involving vasoconstriction
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[31], EC apoptosis via β-ADR signaling [32, 33] and caspase activation [34, 35],
and inhibition of angiogenesis via the modulation of vascular growth factors [33,
36, 37] have been suggested.

1.3

β-adrenergic receptors (β-ADRs)

Propranolol has been known to bind to β-ADRs.

β-ADRs are a family of G

protein-coupled receptors (GPCRs) that mediate physiological responses to
adrenaline and noradrenaline.

It has been previously shown that the

transmembrane region of β-ADRs play a critical role in determining the binding of
selective agonists/antagonists [38]. To date, three subtypes of β-ADRs have
been identified: β1-3 ADRs. There is limited information available on β1-3 ADR
distribution at the cellular and tissue levels.

Highest levels of β1-ADR are

thought to be observed in the heart and brain [39].

β2-ADR shows a wide

distribution pattern and β3-ADR is believed to be predominantly expressed in
adipose tissue [40, 41]. In blood vessels, studies have utilized β-ADR antagonist
binding to show sites in all cellular layers of vessels [42, 43]. Predominant ADR
subtypes in vessels include β1- and β2- as confirmed by β-ADR subtype
knockout studies [42]. Using immunohistochemistry, β1- and β2-ADR proteins
have been localized to IH endothelium (co-localized to CD31-positive cells) as
well as perivascular cells (co-localized to α-smooth muscle actin-positive cells)
[44, 45]. In addition, β3-ADR has also been reported in all phases of IH [37].
Given that β-ADRs are present in normal vessels and IH vessels, the question
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arises as to the role of β-ADRs in vessel function and the effect of β-ADR
blockade in IH resolution.
1.3.1

β-ADR signaling events

β-ADRs associate with downstream signaling molecules upon activation (Figure
1). β1 and β3 generally couple with Gs (stimulatory) proteins, whereas β2 may
couple with Gs or Gi (inhibitory). In the unstimulated state, the trimeric G protein
is bound to GDP. Activation of ADRs promotes exchange of GDP for GTP. The
G protein α subunit with bound GTP then dissociates from the β and γ subunits
to activate adenylate cyclase (AC) and increase intracellular cyclic adenosine
monophosphate (cAMP) levels. Gi may counteract this increase by inhibiting AC.
Intracellular cAMP activates cAMP-dependent protein kinase A (PKA) which may
have multiple cellular consequences [46]. For example, PKA has been shown to
be involved in elaboration of angiogenic factors through cAMP response
element-binding protein (CREB) [47].

In addition to PKA-mediated signaling,

activated AC may also activate mitogen-activated protein kinase (MAPK)
pathway through exchange protein activated by adenylate cyclase (EPAC) [48,
49].

Dissociated Gβγ may also lead to activation of phosphatidylinositol-4,5-

bisphosphate 3-kinase (PI3 kinase) and Akt/protein kinase B. Interestingly, it has
been shown that Akt activation can ultimately increase vessel size and
angiogenesis [50].

In addition, ADR signaling may entail a G protein

independent signaling pathway. A well-characterized example is the β-arrestinmediated activation of MAPK pathways [51, 52]. Involvement of these pathways
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indicates that inhibiting β-ADR through propranolol in IH may, indeed, have
beneficial effects by reducing cell survival as well as inhibiting angiogenesis.

Figure 1: Schematic illustrating β-ADR signaling.
Ligand binding to β-ADRs results in Gs-mediated activation of adenylate cyclase
(AC) and conversion of ATP into cAMP. Intracellular cAMP activates PKA to
phosphorylate target proteins.

cAMP may also activate exchange protein

activated by adenylate cyclase (EPAC) leading to mitogen-activated protein
kinase signaling pathway and downstream effects on cellular processes.
Another pathway activated by β-ADRs is the PI3 kinase and protein kinase B (Akt)
pathway.

In addition to G protein-mediated signaling, β-ADRs may also

participate in G protein-independent signaling through β-arrestin and MAPK.
Figure reproduced from Kum JJY, Khan ZA.

Mechanisms of propranolol action in

infantile hemangioma. Dermato-Endocrinology. 2015; 6:1, e979699.
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1.4

Hemangioma-derived endothelial cells (HemECs)

Exposure of endothelial cells (ECs) isolated from hemangioma specimens to
propranolol has been shown to induce apoptosis [53].

This is evident upon

exposure to 100 µM propranolol in the culture media [35, 53]. Previous literature
has found significant increase in caspase-3 and -9 cleavage products, but not
caspase-8 cleavage following propranolol exposure, suggestive of an intrinsic
apoptotic pathway mediated by propranolol [53]. However, other studies have
found an increase in protein and mRNA levels of caspase-8 [35], indicative of
both intrinsic and extrinsic involvement of the apoptotic pathway. At the mRNA
level, it was reported that propranolol induces expression of apoptotic genes,
such as Bax, p53, caspase-8, and cytochrome c in hemangioma ECs that may
be responsible for its apoptotic effect [35, 53]. These studies have essentially
examined the effect of propranolol without the addition of β-ADR stimulation.
This may suggest a constitutively active β-ADR pathway. A caveat worth noting
here is that these ECs are considered to be hemangioma tumour-derived
(hemECs).

Because there is no specific marker or cellular activity of

hemangioma tumour ECs, it is possible that these cultures may represent a
heterogeneous population of tumoural and non-tumoural ECs (recruited or
angiogenic cells). Interestingly, propranolol’s effect is not specific to hemECs, as
it has been shown to cause apoptosis in a similar manner in other EC types as
well including normal human dermal ECs [32, 54].
In

addition

to

caspase-mediated

apoptosis,

propranolol

may

block

phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR-2) [55].
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It was found that when hemECs were challenged with higher concentrations of
propranolol (50 and 100 µM), the expression of vascular endothelial growth factor
(VEGF) at the protein level was reduced in a dose-dependent manner [53, 56].
This reduction in the level of activated VEGFR-2 and VEGF protein upon
propranolol exposure was a critical element that affected the survivability of these
hemECs [55, 57]. In addition, decrease in key cyclin levels and an increase in
cell cycle inhibitor levels were observed [55]. This suggested that cell cycle
regulation is also another mechanism involved in mediating propranolol’s
therapeutic effect. HemECs show a greater proportion of cells in the G1 phase
than the S/G2 phase when treated with propranolol [32, 55]. This was further
confirmed with decreased expression of cyclin proteins such as cyclins A1, A2,
B2, D1, D2, D3 [32, 55], while cell cycle inhibitor proteins p15, p21, p27 [55],
were up-regulated.
Many studies have gone in-depth with analyzing the expression levels of the
different β-ADR subtypes. It has been shown that hemECs and other EC types
express both β1- and β2-ADRs at very similar levels, but not β3 [55, 58]. Despite
the various β-ADRs expressed, it is believed that the main mechanism of action
of propranolol in hemECs may involve β1 and/or β2-ADR pathway. A recent
report has shown that ICI-118551 (selective β2-ADR antagonist) was more
effective than metaprolol (selective β1-ADR antagonist) in inhibiting hemECs
proliferation [59].
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1.5

Hemangioma-derived pericytes (HemPericytes)

Pericytes are cells that control EC proliferation and survival by stabilizing the
vascular wall and releasing pro-survival signals [60].

In addition, pericytes

promote survival of ECs through vascular endothelial growth factor A (VEGF-A)
signaling and Bcl-w [61]. It is known that addition of β-ADR agonists and cAMP
analogues can induce relaxation of pericytes [62]. Recently, pericytes isolated
from hemangiomas (hemPericytes) have also been tested for a potential role in
propranolol-mediated vascular regression. When hemPericytes were exposed to
propranolol, epinephrine-induced relaxation was prevented [63]. Furthermore,
the proliferative capacity of hemPericytes was reduced. These pericytes also
expressed β2-ADRs on their cell surface [63].

With knockdown of β2-ADR,

hemPericytes lost epinephrine-induced relaxation and propranolol had no effect
[63]. This suggested that β2-ADR is involved with relaxation and contractility of
hemPericytes in response to propranolol [63]. In addition, when hemPericytes
co-implanted with hemECs were exposed to propranolol, propranolol decreased
the vascular volume indicative of increased vasoconstriction [63]. This may be
suggestive of a possible mechanism by which propranolol causes increased
constriction of the vasculature in IH to reduce the blood flow to the tumor, limiting
its growth.
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1.6

Hemangioma-derived stem cells (HemSCs)

We have shown that IHs are derived from multipotential stem cells termed
hemangioma stem cells (hemSCs) [10]. Clonally expanded hemSCs differentiate
into ECs and produce Glut1-positive microvessels in immunodeficient mice.
Interestingly, hemECs are unable to produce microvessels in nude mice showing
that hemangioma initiating cells are hemSCs. Binding of VEGF-A and vascular
endothelial growth factor B (VEGF-B) to vascular endothelial growth factor
receptor 1 (VEGFR-1) expressed on the surface of hemSCs has been shown to
be required for the induction of hemSCs to EC differentiation, and for blood
vessel formation [64]. Immunostaining of IH specimens shows co-labelling of EC
markers and stem cell markers indicative of an immature EC phenotype in IH [13].
Therefore, these cells represent the true cellular target to understand the
mechanism of propranolol action in hemangiomas.

1.7

Effect of propranolol in other neoplasms

The progression of various cancers has been associated with alteration of β-ADR
signaling pathways.

Hence, β-blockers have been proposed as therapeutic

agents for various cancers.

Pediatric melanoma is a rare disease but its

incidence has increased in the young population. Melanoma is accountable for
up to 3% of all pediatric malignancies [65]. Similar to IH, melanoma cases are
more commonly diagnosed in Caucasian and female patients [66], and almost
20% of malignant melanoma occurs in the head and neck region [67].
Melanocyte stem cells (MelSCs) generate melanocytes that produce melanin-
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pigment throughout adult life. The pathogenesis of melanoma is still subject to
debate, but many have suggested mutations in MelSCs involving the cell cycle
and apoptosis pathways, such as tumour protein p53 pathways, and stressors
that increase catecholamines are involved in tumour progression [68, 69].
The increase in norepinephrine and epinephrine primarily modulates the β-ADR
pathways through PKA and MAPK signaling mechanisms, ultimately affecting the
growth and progression of melanoma [70].

Additionally, increase in the

expression of VEGF, interleukin (IL) -6 and IL-8 after catecholamine stimulation
correlates with the aggressiveness of the tumour [70, 71].

Melanoma cells

express both β1- and β2-receptors with β1-ADR expression being weaker
relative to β2-ADR [68, 70]. Recently, β3-ADRs have been proposed to be
involved in melanoma growth and vascularization [72], and the use of β-blockers
in malignant melanoma decreased the risk of progression [73]. Although the
exact mechanism underlying the effectiveness of these medications in reducing
tumour progression is unknown, it has been suggested that β-blockers reduce
angiogenic factors and metastatic progression [73].

β-blockers may inhibit

angiogenesis by reducing VEGF activity via MAPK signaling.

In addition, β-

blockers modulate matrix metalloproteinases (MMPs) that can alter the tumour
microenvironment involved with angiogenesis [74]. Recently, specific inhibition
of β3-ADRs in melanoma cells was found to impair cell growth and induce
apoptosis [72].
β-ADR has also been implicated in breast cancer. Breast cancer cells express
both β1- and β2-ADRs [75, 76], and the polymorphisms of β-ADR subtypes may
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be associated with breast cancer susceptibility [77]. Breast cancer patients who
received propranolol for hypertension displayed reduced metastasis and cancer
recurrence [78]. This may be due β-ADR involvement in gene expression within
the primary tumour [79].

Further investigation of β-ADR signaling provided

evidence that the β-ADR pathway controls the stimulation of the arachidonic acid
cascade [80].

In breast cancer development, arachidonic acid is a critical

molecule that has been shown to activate mTOR (mammalian target of
rapamycin) and increase the activity of VEGF [81]. mTOR and VEGF seem to be
a common pathway in breast cancer and in hemECs, involving enhanced
angiogenesis.
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1.8

Rationale

A number of studies have investigated the effect of propranolol on IH-derived
endothelial cells to offer insight into the mechanisms of therapeutic effect of
propranolol [53, 55, 58]. These studies show that propranolol causes apoptosis
in IH endothelial cells by activating caspase-3 and also blocks other cellular
activities including migration and tubule formation [53, 55].

This effect of

propranolol is also exhibited by normal endothelial cells [32, 55].

We have

shown that IH arises from multipotent stem cells [10]. Utilizing stem cell antigen
CD133, we isolated stem cells from hemangiomas and showed that these cells
produce hemangioma lesions in mice. Interestingly, IH-derived endothelial cells
(exhibiting mature endothelial phenotype as assessed by endothelial cell
markers) fail to produce Glut1-positive microvessels [10]. This suggests that the
cell of interest, at least in proliferating phase IH when treatments are required, is
the hemSCs.
It has been observed that all hemangiomas do not respond the same way to
propranolol, as up to 20% of cases of hemangiomas regrow upon cessation of
propranolol treatment [82]. This puzzling finding has been attributed to early
treatment withdrawal and/or long proliferating phase of IH. Since IHs regrow in a
significant proportion of patients that discontinue propranolol treatment [29], it is
possible that hemSCs, unlike hemECs and normal vascular ECs, are not
susceptible to propranolol-induced apoptosis.
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1.9

Hypothesis

We hypothesize that propranolol does not cause apoptosis in hemangioma stem
cells. If true, this may explain why recurrence of these tumours often occurs
following cessation of treatment.
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Chapter 2
2

Materials and Methods

2.1

Infantile hemangioma specimens and immunostaining

All studies were conducted following approval by the Research Ethics Board at
Western University, London, Ontario, Canada. Paraffin-embedded IH specimens
were obtained from the Department of Pathology Archives at the London Health
Sciences Centre (LHSC, London Ontario, Canada). The proliferating phase was
confirmed through medical history, physical examination, and histological
analysis of densely packed capillaries.

In addition, all hemangioma sections

were immunostained with Glut1 to confirm diagnosis.

Tissue sections were

deparaffinized, hydrated, and subjected to antigen retrieval using Tris/EDTA
buffer (10 mM Trizma-base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) in 2100
Retriever (Electron Microscopy Sciences, Hatfield, PA).
Slides were incubated slides with mouse anti-human CD31 (1:50; M0823, Dako
Canada, Mississauga, ON) and rabbit anti-human CD133 antibody (1:100;
ab19898, Abcam, Cambridge, MA) for 1 hour at room temperature. Fluoresceinor texas red-conjugated secondary antibodies (Vector Laboratories, Burlington,
ON) were used for detection.
Laboratories).

Slides were counterstained with DAPI (Vector

Images were taken using the Olympus BX-51 microscope

(Olympus Canada In., Richmond Hill, ON) equipped with a Spot Pursuit digital
camera (SPOT Imaging Solutions, Sterling Heights, MI).
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2.2

Infantile hemangioma cell culture

Proliferating IH-derived CD133+ cells (hemSCs) were provided by Dr. Joyce
Bischoff (Children’s Hospital Boston, Boston, MA).

We have previously

characterized these cells through qRT-PCR, immunostaining, and cellular activity
assays [83]. Freshly isolated human bone marrow-mesenchymal progenitor cells
(bm-MPCs; isolated from bone marrow mononuclear preparations; 2M-125B,
Lonza Inc., Walkersville, MD) were used as normal stem/progenitor controls.
Neonatal human dermal microvascular endothelial cells (HDMECs; CC-2516,
Lonza Inc.) were also used as controls. All cells were cultured on fibronectincoated (FN; 1 µg/cm2, FC010-10, Millipore, Temecula, CA) plates in complete
EBM2 media (Lonza) supplemented with 20% fetal bovine serum (Lonza), EGM2 SingleQuots (CC-4176, Lonza Inc.) and 1X antibiotic antimycotic media (PSF;
Life Technologies).

Cells were cultured under identical conditions and

experiments were performed with a minimum of 2 biological replicates (different
IH cell preparations) and 3 technical replicates.
2.2.1

Cell growth assay

To determine the effect of propranolol on cellular growth and survival, we plated
each cell type at 5000 cell/cm2 in complete EBM2 growth media (described
above). After 24 hours, media was removed and cells were exposed to the
following

treatments:

(RS)-1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-

propanol hydrochloride (25, 50, or 100 µM Propranolol; 0624, R&D Systems,
Minneapolis, MN); CGP 20712 dihydrochloride (10 nM CGP; 1024, Tocris
Bioscience); ICI 118,551 hydrochloride (10 nM ICI; 0821, Tocris Bioscience);
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nadolol (25, 50, or 100 µM; 253175, Santa Cruz); 5-carboxamidotryptamine
maleate (200 nM or 1 μM 5-CT; 0458, Tocris Bioscience, Bristol, UK); SDZ
21009 (200 nM or 1 μM SDZ; 1516, Tocris Bioscience); (S)-(6-Methoxyquinolin4-yl)((2R,4S,8R)- 8-vinylquinuclidin-2-yl)methanol hydrochloride (1, 25, 50, or
100 µM Quinidine; 4108, Tocris Bioscience) in fresh EBM2 media (Table 1).
Number of live cells was determined at 24 or 72 hours using Scepter 2.0
Automated Cell Counter (Millipore) with appropriate histogram gating setup [84,
85].

Data were normalized to each respective control groups as multiple

experiments were performed in various plate sizes.
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Table 1: List of treatments used
Name

Concentration

Function

25 µM
Propranolol

50 µM

β1/2-ADR antagonist

100 µM
CGP

10 nM

β1-ADR antagonist

ICI

10 nM

β2-ADR antagonist

5-CT

SDZ

200 nM
1 μM

5-HTR 1/7 agonist

(CAS 3506-09-0)
Tocris
(CAS 1216905-73-5)
Tocris
(CAS 72795-01-8)
Tocris
(CAS 74885-72-6)

5-HTR antagonist

Tocris

1 μM

potent activity for 1A/1B

(CAS 39731-05-0)

50 µM

Santa Cruz
β1/2-ADR antagonist

100 µM
1 μM
Quinidine

Tocris

200 nm

25 µM
Nadolol

Source

25 µM
50 µM
100 µM

Biotechnology
(CAS 42200-33-9)

Class 1A antiarrhythmic
agent (Membrane
stabilizing agent)

Tocris
(CAS 56-54-2)
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2.2.2

Cellular transfection

To transfect the cells with silencing RNA, we coated 12-well plates with basal
EBM2 media (Lonza) supplemented with 20% fetal bovine serum (Lonza), EGM2 SingleQuots (CC-4176, Lonza Inc.) without GA-1000 (gentamicin sulfate; CC4381a, Lonza) and 1X antibiotic antimycotic media (PSF; Life Technologies)
(EBM2 antibiotic/antimycotic free media) for 30 minutes on the day of
transfection. The cells were transfected with either control siRNA-A (sc-37007,
Santa Cruz, Santa Cruz, CA), β1-adrenergic receptor siRNA (sc-29580, Santa
Cruz), or β2-adrenergic receptor siRNA (sc-39866, Santa Cruz) at a
concentration of 200 nM.
electroporation
Technologies).

device

Cells were transfected with siRNA using an

(Neon®

Transfected

Transfection

cells

were

System,

incubated

MPK5000S,
for

24

hours

Life
in

antibiotic/antimycotic-free EBM2 media. After 24 hours, complete EBM2 media
was added. After 24 or 72 hours of culture, cells were collected for total number
of live cells and for RNA isolation. β1- or β2-ADR knockdown was confirmed by
qRT-PCR. Identical protocol was used to transfect both hemSCs and HDMECs.

2.3

RNA isolation, mRNA profiling & quantitative RT-PCR

RNA was isolated using Aurum Total RNA isolation kit (Bio-Rad) or RNeasy
Micro Plus Kit (Qiagen, Mississauga, ON). RNA was measured using Qubit RNA
Broad Range Assay in a Qubit Fluorometer (Life Technologies). cDNA was then
synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA). We performed gene expression analyses using RT 2 Human Cell Death
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Pathway Finder PCR arrays (PAHS-212Z; Qiagen) (Table 2).

Data was

analyzed by CFX Manager Software using normalized (ΔΔCT) method with two
housekeeping genes (β-actin and GAPDH were both used for normalization after
empirically determining the expression for stability in our treatment groups).
Various receptor levels and downstream signaling gene expression was
assessed by qRT-PCR (Table 2,3).

Reactions consisted of 10 µL ssoFast

Evagreen (1725200, Bio-Rad), 2 µL of both forward and reverse primers (at a 10
µM concentration), 2 µL cDNA, and 6 µL of H2O. Target gene mRNA data was
normalized to β-actin (QT01680476, Qiagen). All reactions were performed for
40 cycles using the following temperature profiles: 95°C for 2 minutes (initial
denaturation); and 60°C for 30 seconds (annealing and extension). Data was
analyzed using normalized (ΔΔCT) method or relative quantity (ΔCT).
Adipogenesis-specific gene expression was also assessed by qRT-PCR (Table
2).

Adipogenesis was assessed by C/EBPα (QT00203357, Qiagen) and

PPARγ2 (sequence shown in [86]). Target gene mRNA data was normalized to
β-actin (QT01680476, Qiagen). All reactions were performed for 40 cycles using
the following temperature profiles: 95°C for 2 minutes (initial denaturation); and
55°C for 12 seconds (annealing and extension).
relative quantity (ΔCT).

Data was analyzed using
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Table 2: List of primers used
Gene
B-cell CLL/lymphoma 2

Length (bp)

Source (catalogue #)

108

Bio-Rad (qHsaCED0057245)

Actin, beta (β actin)

104

Qiagen (QT01680476)

Cyclin-D1 (CCND1)

96

Qiagen (QT00495285)

CCAAT/enhancer binding

88

Qiagen (QT00203357)

113

Qiagen (QT00029841)

138

Qiagen (QT00085379)

139

Qiagen (QT00085001)

138

Qiagen (QT00082138)

112

Qiagen (QT00204309)

136

Qiagen (QT00200011)

86

Qiagen (QT00200004)

(BCL2)

protein alpha (C/EBPα)
Peroxisome proliferatoractivated receptor gamma 2
(PPARγ2)
v-akt murine thymoma viral
oncogene homolog 1 (AKT 1)
v-akt murine thymoma viral
oncogene homolog 2 (AKT 2)
v-akt murine thymoma viral
oncogene homolog 3 (AKT 3)
Beta-1-adrenoceptor
(β1-ADR)
Beta-2-adrenoceptor
(β2-ADR)
Beta-3-adrenoceptor
(β3-ADR)

Plate
RT2 Human Cell Death
Pathway Finder PCR arrays

Qiagen (PAHS-212X)
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Table 3: List of primers used in customized plate
Gene

Length (bp)

Source (assay ID)

Housekeeping gene
Actin, beta (ACTB)

62

Bio-Rad (Hs.520640)

96

Bio-Rad (Hs.709175)

112

Bio-Rad (Hs.368632)

140

Bio-Rad (Hs.557)

102

Bio-Rad (Hs.249159)

119

Bio-Rad (Hs.247686)

145

Bio-Rad (Hs.123022)

94

Bio-Rad (Hs.99913)

82

Bio-Rad (Hs.2551)

77

Bio-Rad (Hs.2549)

143

Bio-Rad (Hs.525622)

71

Bio-Rad (Hs.631535)

Adrenergic Receptors
adrenergic, alpha-1A-, receptor
(α1A-ADR)
adrenergic, alpha-1B-, receptor
(α1B-ADR)
adrenergic, alpha-1D-, receptor
(α1D-ADR)
adrenergic, alpha-2A-, receptor
(α2A-ADR)
adrenergic, alpha-2B-, receptor
(α2B-ADR)
adrenergic, alpha-2C-, receptor
(α2C-ADR)
adrenergic, beta-1-, receptor
(β1-ADR)
adrenergic, beta-2-, receptor
(β2-ADR)
adrenergic, beta-3-, receptor
(β3-ADR)

Downstream signaling molecules
v-akt murine thymoma viral
oncogene homolog 1 (AKT1)
v-akt murine thymoma viral
oncogene homolog 2 (AKT2)

23

v-akt murine thymoma viral

97

Bio-Rad (Hs.498292)

B-cell CLL/lymphoma 2 (BCL2)

108

Bio-Rad (Hs.150749)

Cyclin-D1 (CCND1)

143

Bio-Rad (Hs.523852)

cAMP responsive element

76

Bio-Rad (Hs.516646)

74

Bio-Rad (Hs.631630)

88

Bio-Rad (Hs.487325)

84

Bio-Rad (Hs.158029)

oncogene homolog 3 (AKT3)

binding protein 1 (CREB1)
protein kinase, cAMP-dependent,
catalytic, alpha (PRKACA)
protein kinase, cAMP-dependent,
catalytic, beta (PRKACB)
protein kinase, cAMP-dependent,
catalytic, gamma (PRKACG)

5-hydroxytryptamine (Serotonin) receptors
5-hydroxytryptamine (serotonin)

86

Bio-Rad (Hs.247940)

108

Bio-Rad (Hs.123016)

89

Bio-Rad (Hs.121482)

99

Bio-Rad (Hs.1611)

73

Bio-Rad (Hs.248136)

63

Bio-Rad (Hs.654586)

81

Bio-Rad (Hs.421649)

144

Bio-Rad (Hs.149037)

receptor 1A (HTR1A)
5-hydroxytryptamine (serotonin)
receptor 1B (HTR1B)
5-hydroxytryptamine (serotonin)
receptor 1D (HTR1D)
5-hydroxytryptamine (serotonin)
receptor 1E (HTR1E)
5-hydroxytryptamine (serotonin)
receptor 1F (HTR1F)
5-hydroxytryptamine (serotonin)
receptor 2A (HTR2A)
5-hydroxytryptamine (serotonin)
receptor 2B (HTR2B)
5-hydroxytryptamine (serotonin)
receptor 2C (HTR2C)

24

5-hydroxytryptamine (serotonin)

140

Bio-Rad (Hs.413899)

97

Bio-Rad (Hs.483773)

105

Bio-Rad (Hs.65791)

150

Bio-Rad (Hs.22180)

142

Bio-Rad (Hs.73739)

receptor 3A (HTR3A)
5-hydroxytryptamine (serotonin)
receptor 4 (HTR4)
5-hydroxytryptamine (serotonin)
receptor 5A (HTR5A)
5-hydroxytryptamine (serotonin)
receptor 6 (HTR6)
5-hydroxytryptamine (serotonin)
receptor 7 (HTR7)
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2.4

Protein quantification

Total proteins from the cultured cells were extracted using Cell Extraction Buffer
(Life Technologies) with complete protease inhibitor cocktail (Roche Diagnostics,
Laval, Quebec).

Proteins were measured by BCA Protein Assay Reagent

(Pierce BCA Protein Assay Kit, Thermo Scientific, Rockford, IL) and equal
amounts were used for various protein measurements.
2.4.1

Caspase-3 and Cyclin-D1 measurements

To measure activated caspase-3, caspase-3 (active) Human ELISA kit (Life
Technologies) was used. Data were collected using Thermo Scientific Multiskan
FC Microplate Photometer (Thermo Scientific), measuring absorbance at 450nm.
Cyclin-D1 level was measured similarly using PathScan Total Cyclin-D1
Sandwich ELISA kit (Cell Signaling Technology Inc., Danvers, MA).
2.4.2

Protein Kinase A Activity measurement

To quantify Protein kinase A (PKA) activity, PKA Kinase Activity kit (Abcam) was
used.

Data were collected using Thermo Scientific Multiskan FC Microplate

Photometer (Thermo Scientific), measuring absorbance at 450nm.

26

2.5

Adipogenic Differentiation

To induce adipogenic differentiation, hemSCs were seeded at a density of
40,000 cells/cm2 in StemPro Adipogenesis differentiation media (Adipo media;
Life Technologies).

Control media consisted of Dulbecco's Modified Eagle

Medium supplemented with 10% FBS. Media was changed every other day.
RNA was isolated from cells after 7 days to perform qRT-PCR for β-adrenergic
receptor expression. To determine whether cell growth/proliferation may alter
adipogenesis, we pretreated hemSCs with 10 μg/mL mitomycin C (MitoC; Sigma
Aldrich, Oakville, ON) for 2 hours. Cells were then washed, resuspended, and
plated at 40,000 cells/cm2 in adipogenesis media. RNA was isolated at day 4 to
assay for C/EBPα and PPARγ2 levels (transcription factors essential for
adipogenic differentiation).

2.6

Statistical Analysis

The data were expressed as means ± SEM.

Where appropriate, student’s

unpaired t-tests or analysis of variance (ANOVA) were performed. P values <
0.05 were considered statistically significant.
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Chapter 3
3

Results

3.1

Atypical phenotype of hemangioma endothelium

Previous studies have investigated the effect of propranolol on IH-derived
endothelial cells to offer insight into its mechanism of therapeutic effect [53, 55,
58]. However, we have shown that CD133-selected cells from human IH initiate
hemangioma lesions in mice, producing Glut1-positive microvessels [10]. This
suggests that the mechanism of therapeutic effect of propranolol needs to be
investigated on hemSCs. Therefore, we performed immunostaining for CD133 to
probe for microvessels that are lined by CD133-expressing cells (hemangioma
vessels). Results from two proliferating IH specimens show that all microvessels
within IH tissues are immunoreactive to CD133 (Figure 2). This suggested that
for understanding the effect of propranolol, CD133-selected hemSCs are
essential.
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Figure 2: Hemangioma vessels are lined with CD133-positive cells.
Proliferating

hemangioma

immunostaining.

specimens

were

characterized

through

Hemangioma specimens were double labeled for CD31

(endothelial cell marker; red) and CD133 (stem cell antigen; green).

4′,6-

Diamidino-2-phenylindole (blue) was used as counterstain. Staining illustrates
complete co-localization of CD31 and CD133 in both proliferating hemangioma
specimens (images were taken at magnification of ×20; insets illustrate high
magnification; bar = 200 μm). Human skin and placenta were used as negative
and positive controls respectively for CD133 (Data not shown).
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3.2

Propranolol inhibits hemSCs growth

Our next objective was to determine the effect of propranolol on the growth of
hemSCs. We cultured the cells with 25, 50, or 100 µM propranolol and assayed
for live cell number at both 24 and 72 hours. We chose these concentrations
based on previous studies that have observed significant differences in IH
endothelial cells [32, 55]. Furthermore, propranolol has been shown to have
immediate effects in inhibiting cell viability at 24 hours [53]. Interestingly, no
significant changes to cell number were observed in hemSCs at 24 hours (Figure
3A). At 72 hours, bm-MPCs and HDMECs showed significant reductions in cell
number at all concentrations of propranolol when compared to control (Figure
3B). In contrast, a proliferative effect was observed when hemSCs were treated
with 25 µM propranolol and a reduction in live cell number with 100 µM
propranolol (Figure 3B).
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Figure 3: 100 μM propranolol reduces hemSCs growth after 72 hours.
Live cell number after (A) 24 hours and (B) 72 hours of treatment with different
concentrations of propranolol. Propranolol treatment at 100 μM reduced number
of cells compared with control after 72 hours. (*P < 0.05 compared with
respective control).
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3.3

Reduced cell number following propranolol treatment is not due to
apoptosis in hemSCs

As the cell number decreased significantly for all cell types when cultured in 100
µM propranolol (at 72 hours), we examined whether this was due to apoptosis.
Therefore, cells treated with propranolol were assayed for active caspase-3.
Caspase-3 is the most frequently activated death protease and has been shown
to play a role in inducing endothelial cell apoptosis upon propranolol treatment
[53, 55].

Unexpectedly, hemSCs treated with 100 µM propranolol showed a

significant reduction in the level of active caspase-3. This suggested that in
hemSCs, the reduction in cell number might be due to inhibited cell growth and
not apoptosis. bm-MPCs did not show a significant difference upon propranolol
treatment as caspase-3 levels remained unchanged (Figure 4A). On the other
side of the spectrum, propranolol-treated HDMECs showed a significant increase
in the level of activated caspase-3 as expected. These data demonstrate that
propranolol treatment induces apoptosis in HDMECs, whereas the decrease in
cell number in hemSCs and possibly bm-MPCs is mediated by a reduction in cell
growth.
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3.4

Propranolol halts cell cycle progression but does not induce
apoptosis in hemSCs

We examined the effect of propranolol on cyclin-D1 level. Cyclin-D1 is a key
regulator in the progression from G1/S phase and has recently been shown to be
maintained in G2 phase [87].

Recent studies have shown that propranolol

reduces cyclin-D1 in a time-dependent manner in endothelial cells [32].
Surprised by previous experimental findings, we wanted to determine if
propranolol reduces cyclin-D1 in hemSCs.

Our results do show significantly

reduced cyclin-D1 in hemSCs upon propranolol treatment (Figure 4B). Similarly,
bm-MPCs and HDMECs cyclin-D1 levels were also significantly reduced (Figure
4B). The greatest change in cyclin-D1 was seen in bm-MPCs which may explain
the reduced cell number seen earlier. These results suggest that propranolol
inhibits cell cycle progression in all cell types by decreasing level of cyclin-D1.
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Figure 4: Propranolol inhibits caspase-3-mediated apoptosis in hemSCs.
Levels of (A) active caspase-3 and (B) cyclin-D1 in hemSCs, bm-MPCs, and
HDMECs following 100 μM propranolol treatment for 72 hours by ELISA.
(*P < 0.05 compared with respective control).
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3.5

Propranolol induces anti-apoptotic pathways in hemSCs

In order to understand the possible mechanism by which propranolol induces
apoptosis in endothelial cells but not hemSCs, we used quantitative RT-PCR to
profile for genes important in the central mechanisms of cellular death. We used
a Human Cell Death Pathway Finder PCR Array (Qiagen; see Methods for
details) which comprises 84 key genes important for cell survival and apoptosis.
HemSCs, bm-MPCs, and HDMECs were cultured in normal growth media or in
media containing different concentrations of propranolol for 72 hours. Using this
PCR-based array, we found that propranolol significantly induces various antiapoptotic pathways in hemSCs and normal bm-MPCs (Figure 5). These included
Akt (also known as protein kinase B; induced 31.2x in hemSCs, 7.58x bm-MPC),
Bcl2 (295.9 x in hemSCs, 143.2x bm-MPC)/Bcl2A (23.4x in hemSCs, 10.9x in
bm-MPC), and insulin-like growth factor receptor-1 (IGFR1, 53.6x in hemSCs,
9.2x in bm-MPC). In contrast, we did not observe any alteration of these antiapoptotic pathways in HDMECs (Figure 5).
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Figure 5: Propranolol induces anti-apoptotic signaling pathways in
hemSCs.
Propranolol induced the expression of anti-apoptotic genes in hemSCs and bmMPCs but not in HDMECs. (mRNA levels were measured using RT2 Cell Death
Pathway Finder (Qiagen, Mississauga, ON) and normalized to β-actin and
glyceraldehyde 3-phosphate dehydrogenase levels; red dashed lines highlight
100 μM propranolol groups; graph shown are representative of multiple PCR
arrays).
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3.6

β2 and β3 are the predominant β-ADRs in hemSCs

We next assayed for β-ADR expression in hemSCs and compared the levels to
mature endothelial cells. Our results show that hemSCs express both β2- and
β3-ADRs (Figure 6).

β1-ADR mRNA levels, although detectable, were

significantly lower. Interestingly, we found that bm-MPCs share β-ADR profile
with hemSCs. Mature endothelial cells (human microvascular endothelial cells;
HDMECs) on the other hand exhibited higher level of β1-ADR expression (Figure
6). No significant differences were found in the level of β2- or β3-ADRs between
endothelial cells, hemSCs, and bm-MPCs.
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Figure 6: β2/3-ADRs are predominantly expressed in hemSCs.
qRT-PCR analysis of β-ADRs in hemSCs, bm-MPCs, and HDMECs were
determined

by

real-time

quantitative

reverse-transcriptase

PCR.

(Data

normalized to β-actin; *P < 0.05 compared with β1-ADR mRNA levels in hemSCs
and bm-MPCs; †P < 0.05 compared with β2- and β3-ADR mRNA levels). RNA
was isolated from cells cultured in Endothelial Basal Media-2 (EBM2) under
identical conditions.

The specificity of the amplification was determined by

melting curve analysis (Appendix A).
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3.7

β-ADR downstream signaling molecules are detectable, but too low
to quantify in hemSCs

To ensure the effects we observed upon propranolol exposure were through βADR inhibition, we investigated the change in key downstream signaling
molecules upon propranolol exposure. PKA is an important mediator for cellular
processes where its function depends on cAMP. Although we have observed a
linear standard curve for active PKA standards in our study (Figure 7, Table 4),
PKA activity upon 25 and 100 µM propranolol was below the detection limit in
both hemSCs and HDMECs. Even with the addition of 20 ng of exogenous
active PKA in hemSC and HDMEC protein samples, the amount of active PKA
remained below the quantitative limit (Table 5).

Figure 7: Linear standard curve for active PKA standards.
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Table 4: PKA activity in purified PKA standards
PKA Standards
(ng)

Active PKA
amount (ng)

0

0

9.375

9.48

18.75

18.70

Table 5: PKA activity in hemSCs and HDMECs

Cell type

HemSCs

HDMECs

Control

Active PKA amount (ng)
with addition of exogenous
20 ng of active PKA
1.93

25 µM Propranolol

1.93

100 µM Propranolol

2.03

Control

1.13

25 µM Propranolol

1.32

100 µM Propranolol

1.50

Treatment
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3.8

Specific β-ADR antagonist does not affect hemSCs

As β1-ADR was predominantly expressed in the well-differentiated endothelial
cells, we questioned whether specific β1-ADR antagonists can mimic propranolol.
We cultured the cells with 10 nM CGP (β1-selective blocker) and/or ICI (β2selective blocker) and assayed for live cell number after 72 hours. If propranolol
is acting through β1-receptor that is predominantly expressed in endothelial cells,
then we would expect decreased growth in this particular cell type with CGP.
Indeed, our results show that 10 nM of CGP, but not ICI, significantly decrease
cell number when compared with control (Figure 8). When CGP and ICI are
combined to represent propranolol’s non-selective binding characteristic,
HDMEC number is also significantly reduced (Figure 8).

In contrast, no

significant changes to live cell number were observed in hemSCs with all
treatments using specific β-ADR antagonists (Figure 8). This suggests that βADR signaling pathway may not be involved in hemSCs.
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Figure 8: Specific β1- and β2-ADR antagonist does not affect growth of
hemSCs.
Live cell number after 72 hours of treatment with selective β-ADR antagonists.
β1- and β2-selective blockers did not affect the cell number compared to control
in hemSCs. (*P < 0.05 compared to respective control).
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3.9

Specific β-ADR silencing does not affect hemSCs growth

To rule out propranolol’s β-ADR-dependent mechanism of action in hemSCs, we
transfected hemSCs with specific β-ADR silencing RNA (siRNA) in complete
growth media with or without 100 µM propranolol. Similar to specific β-ADR
antagonist use, the growth of hemSCs was not affected upon knockdown of β1and β2-ADR (Figure 9A). However, control and β1 siRNA-transfected hemSCs
exposed to propranolol significantly reduced cell growth. This was not seen with
β2 siRNA-transfected hemSCs cultured in propranolol media (Figure 9A).
In contrast, β-ADR knockdown significantly decreased HDMECs cellular growth
(Figure 9A). Specific β1 siRNA-transfected HDMECs cultured with propranolol
significantly reduced cell number compared to β1 knockdown in complete growth
media (Figure 9A).

Interestingly, β1-ADR knockdown HDMECs cultured with

propranolol significantly increased growth when compared to control transfection
with propranolol (Figure 9A). Our findings indicate live cell number is affected in
HDMECs with β-ADR knockdown, but not hemSCs.
Transfection efficiency was confirmed by qRT-PCR. We were able to achieve
greater than 80% suppression of β2-ADR in hemSCs and HDMECs (Figure
9B,C), and greater than 70% suppression of β1-ADR in HDMECs (Figure 9C).
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Figure 9: Specific β1- and β2-ADR siRNA does not affect growth of hemSCs.
Transfecting hemSCs with β1- and β2-ADR siRNA (A) did not affect growth,
unlike HDMECs. (*P < 0.05 as compared to respective control; †P < 0.05 as
compared to respective β-siRNA; γP < 0.05 as compared to respective control
siRNA with propranolol). (B,C) Knockdown efficiency was measured through βADR mRNA levels. β2-ADR knockdown efficiency was greater than 80% in both
cell types. β1-ADR knockdown efficiency was greater than 70% in HDMECs.
(*P < 0.05 as compared to respective control).
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3.10

5-HTR7 levels are significantly high in hemSCs

To investigate β-ADR-independent mechanism of propranolol, we have profiled
various ADRs and downstream signaling molecules.

We also measured the

expression of 5-HTRs to which propranolol has been shown to bind [88].
Interestingly, all of α- and β-ADR subtypes were significantly lower in hemSCs
when compared to HDMECs (Figure 10A).

As well, majority of downstream

signaling molecules were lower in level in hemSCs, except Bcl2 (Figure 10B).
Similarly, many 5-HTRs were significantly lower in hemSCs, except 5-HTR7
(Figure 11). This hinted to us that propranolol may mediate its effects in hemSCs
through 5-HTR7.
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Figure 10: Low expression of α-ADR, β-ADR, and downstream signaling
molecules in hemSCs.
Gene profiling assay was performed to observe the mRNA levels of (A) α- and βADRs and (B) downstream signaling molecules. (*P < 0.05 compared to
HDMECs).
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Figure 11: 5-HTR7 is highly expressed in hemSCs.
Gene profiling assay was performed to observe the mRNA levels of 5-HTRs.
(*P < 0.05 compared to HDMECs).
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3.11

Serotonin agonist decreases hemSCs growth

Previous literature has reported that propranolol can interact with 5-HTRs
(serotonin receptors) [88].

Therefore, we explored the possibility that the

reduction in cellular growth upon propranolol exposure in hemSCs is mediated
through 5-HTR pathway. Since it is not known whether binding of propranolol to
5-HTRs leads to activation or inhibition, we first tested hemSCs with a selective
5-HTR1/7 agonist, 5-CT, at various concentrations.

Interestingly, both

concentrations of 5-CT significantly reduced live cell number after 72 hours,
similar to propranolol.

If propranolol affected the hemSCs through 5-HTR

pathway, then we would expect no significant difference when we combine
propranolol with 5-HTR antagonist to eliminate propranolol’s effect.

Indeed,

when we combine SDZ with propranolol, the cell number is normalized to control
levels (Figure 12A). Surprisingly, 5-CT at 200 nM had no significant effect on
HDMECs, unlike hemSCs (Figure 12B). This suggests that the two cell types
may exhibit different cellular signaling pathways upon propranolol exposure.
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Figure 12: 5-CT mimics the effect of propranolol in hemSCs growth.
Live cell number after 72 hours of treatment with (A) 5-CT (5-HTR agonist) and
combination of propranolol with SDZ (5-HTR antagonist) in hemSCs and (B) 5CT in hemSCs and HDMECs. (*P < 0.05 compared to respective control).
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3.12

Propranolol-induced altered differentiation in hemSCs

While our studies were underway, a report showed that presence of propranolol
in adipogenic differentiation media increased the differentiation level in hemSCs
as compared to cells in adipogenic media alone [34]. Higher levels of C/EBPβ
and δ were found at day 4. Interestingly, when the cells were maintained in the
differentiation media supplemented with propranolol for 7 days, significant cell
death was observed. This is in contrast to our observations in normal growth
media where a significant reduction in cell number is evident without apoptosis.
Therefore,

we

explored

the

possibility

that

this

enhanced

adipogenic

differentiation with propranolol is mediated through cell growth regulation. To
test this idea, we treated hemSCs with mitomycin C to inhibit proliferation and
tested for C/EBP expression. Our results show that C/EBPα was significantly
higher when mitomycin C-treated hemSCs were exposed to adipogenic
differentiation media for 4 days (Figure 13A).

No change was observed in

PPARγ2 levels. C/EBPα is a critical transcription factor in adipogenesis and
enhanced levels suggest that inhibition of cell proliferation increases the
differentiation capacity of hemSCs and this may be the mechanism underlying
propranolol’s effect. We then assayed for β-ADR expression and show here that
adipogenesis is associated with significantly higher levels of all three ADRs
(Figure 13B).

Therefore, cell death in adipogenic media supplemented with

propranolol [34] might be due to increased expression of β-ADRs, which
accompanies hemSCs differentiation.
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Figure 13: Growth inhibition enhances adipogenesis.
Effect of mitomycin C treatment on adipogenic differentiation (A) in hemSCs at
day 4. (*P < 0.05 compared with control media; †P < 0.05 compared with
adipogenic differentiation media without mitomycin C treatment). (B) Induction of
β-ADRs following adipogenic differentiation in hemSCs at day 7. (*P < 0.05
compared with control media).
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3.13

β-ADR levels change with propranolol exposure

Changes in β-ADR expression upon hemSC differentiation prompted us to
assess the changes in receptor profile in the presence of propranolol. Therefore,
we measured the level of β-ADR mRNA upon 100 µM propranolol exposure after
72 hours. In contrast to what we had expected based on Figure 13 (increase in
β-ADR to increase susceptibility of hemSCs for cell death/cell cycle inhibition),
hemSCs significantly decreased β2-receptor level after propranolol exposure
(Figure 14A).

Furthermore, only β1-ADR level significantly increased upon

propranolol challenge in HDMECs, whereas β2-ADR level did not significantly
differ (Figure 14B). Our findings indicate that the apoptosis of HDMECs with
propranolol media may be due to the increase in β1-ADR (Figure 14B).

In

addition, our observations indicate that propranolol changes the receptor profile
of both cells differently, which may explain why a difference in response is
observed.
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Figure 14: Propranolol alters level of β-ADRs.
Effect of propranolol exposure on β-ADR mRNA levels (A) in hemSCs and (B)
HDMECs after 72 hours. (*P < 0.05 compared to respective control).
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3.14

Nadolol inhibits hemSCs growth

There have been indications that propranolol can cause central nervous systemrelated side effects due to its lipophilic properties [89]. Therefore, we utilized
nadolol, a non-selective β-ADR antagonist that is hydrophilic. It has also been
suggested that due to its inability to cross blood brain barrier, use of nadolol may
be a safer treatment alternative. We cultured the cells with 25, 50, or 100 μM
nadolol and measured cell number at 72 hours. Interestingly, 25 and 100 μM
nadolol significantly reduced hemSC number when compared to control (Figure
15). In HDMECs, only at 100 μM was there a significant decrease in cell number,
suggesting that nadolol may have its effect in our cell types through an
alternative pathway, different from propranolol’s mechanism.
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Figure 15: Nadolol decreases growth of hemSCs.
Live cell number after 72 hours of treatment of hemSCs and HDMECs with
different concentrations of nadolol. Nadolol at 25 μM reduced hemSC number,
while 100 μM reduced both hemSCs and HDMECs compared to respective
controls. (*P < 0.05 compared to respective control).
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3.15

Quinidine decreases hemSCs growth

Propranolol has been observed to have membrane stabilizing effects [90].
Hence, we wanted to examine whether this property mediates the effect of
propranolol. To investigate whether propranolol’s effect in hemSCs is through
stabilizing the membrane, we exposed hemSCs to 1, 25, 50, or 100 μM quinidine,
a membrane stabilizing agent.

Surprisingly, at the lowest concentration of

quinidine we used, 1 μM, there was a significant increase in hemSCs growth;
however, at high concentration of 100 μM, significant reduction of hemSCs
growth was observed (Figure 16).

Surprisingly, HDMECs were unaffected

across the various concentrations of quinidine.

Our findings indicate that

propranolol may mediate its effects in hemSCs through stabilizing the membrane.
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Figure 16: Quinidine affects hemSCs growth.
Live cell number after 72 hours of treatment with different concentrations of
quinidine. Quinidine treatment at 100 μM reduced number of hemSCs compared
to control. (*P < 0.05 compared to respective control).
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Chapter 4
4

Discussion & Future direction

4.1

Discussion

Propranolol is a widely used treatment for IH; however, the mechanism of
therapeutic effect is still unknown. In addition, some IH regrow after stopping
propranolol treatment [29, 30, 91]. In the present study, we have demonstrated
that proliferating hemangioma specimens are atypical in nature as IH
microvessels express endothelial (CD31) and stem cell (CD133) markers (Figure
2). We have also shown that propranolol does not induce apoptosis in CD133expressing hemSCs, as seen in mature/differentiated endothelial cells (Figure
4A). This suggests that the direct effect of propranolol in IHs may be through
modulating mature endothelial cells and angiogenesis. The mechanism by which
hemSCs and possibly normal progenitor cells (modeled here by bm-MPCs)
escape apoptosis may include induction of anti-apoptotic pathways, a novel
mechanism we have observed (Figure 5). We found Akt, Bcl2/Bcl2A, and IGFR1
to be significantly induced in hemSCs and bm-MPCs.

Akt induction is of

particular importance here as this pro-survival kinase counteracts caspase-3
activity [92-94]. Bcl2 downregulation has been shown to increase caspase-3 in
breast cancer cells [95]. Furthermore, Bcl2A mediates anti-apoptotic effects of
fibroblast growth factor in chrondogenic progenitor-like cell line [96]. Therefore,
these pathways may be involved in reducing/counteracting caspase-3 activity in
hemSCs that is not evident in mature endothelial cells.
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Another interesting finding of this study is that hemSCs predominantly express
β2- and β3-ADRs (Figure 6). β1-ADR levels are almost ten-fold lower. Vascular
endothelial cells, on the other hand, express significantly high level of β1receptor compared to β2/3. These findings suggest that the differential effect of
propranolol in hemSCs and endothelial cells may be due to distinct roles of βADR subtypes. Studies have shown that β1- and β2-ADR have opposing effects
on regulating apoptosis [97-99]. For example, Communal et al. have shown that
activation of β1-receptors on cardiac myocytes induces apoptosis, whereas β2ADR activation opposes cell death [97]. Although this study involved activation
of β-ADR and not antagonism, the concept of a distinct, receptor subtype-specific
role is pertinent here. Moreover, Panjala et al. have demonstrated that β1-ADR
knockout mice exhibit increased formation of degenerate capillaries in retina
[100]. These are interesting findings because retinal endothelial cells express
β1-ADR but not β2 [101]. Also associated with acellular capillaries in the retina
in knockout mice were increased level of cleaved caspase-3. Based on our data,
we suggest that antagonizing β1-receptor in IH endothelial cells is associated
with cell death while β2 may be involved in cell cycle regulation (Figure 17). We
know that hemSCs predominantly express β2- and β3-receptors and show
almost 10-fold lower β1-level (Figure 6). bm-MPCs showed a similar response to
propranolol in cellular activity and molecular alterations, and share the β-ADR
profile with hemSCs (Figure 5,6).
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Figure 17: Proposed mechanism of therapeutic effect of propranolol.
Schematic illustrating the proposed mechanism of propranolol action on hemSCs
and mature endothelial cells. (A) Diagram illustrating the penetrance of apoptotic
effect of propranolol in hemangioma regression.

(B) Propranolol leads to

apoptosis in endothelial cells and other mature cell types, including adipocytes,
through alteration of β1-ADR signaling. Engagement of β2- (and possibly β3-)
ADRs in ECs leads to cell cycle arrest and growth inhibition (potentially through
decreasing cyclin-D1). Propranolol may also activate of 5-HTRs in hemSCs.
(?

denotes

unclear

mechanism

through

5-HTR

pathway).

Figure modified from Kum JJY, Khan ZA. Propranolol inhibits growth of hemangiomainitiating cells but does not induce apoptosis. Pediatric Research. 75:381-8.
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A recent report by Ji et al. have shown that ICI-118551 (a selective β2-ADR
antagonist) was more effective than metaprolol (selective β1-antagonist) in
inhibiting hemECs proliferation [59]. However, our data suggests the opposite.
β1-antagonist decreases cell growth, whereas β2-antagonist had no effect in
HDMECs (Figure 8).

When β1 and β2 specific antagonists were given

simultaneously, it had less of an impact on the growth compared with β1antagonist alone (Figure 8). As mentioned earlier, a similar phenomenon has
been reported in cardiac myocytes where β1-receptors induce apoptosis and β2ADR activation opposes cell death [102].

Our findings indicate that the key

mediator in promoting apoptosis in mature endothelial cells is β1-ADRs.
To ensure the inhibition of β-ADR with propranolol in our model system, we
measured for the downstream signaling molecule, PKA. Previous studies have
shown that pre-treatment with β-agonist followed by β-antagonist can decrease
cAMP levels in a dose-dependent manner [58]. However, our study suggests
that without exogenously activating the β-ADR system, the cells do not exhibit
sufficient β-ADR downstream signaling (Figure 8). We transfected our cells with
β-ADR siRNA to determine whether propranolol mediates its effects directly
through modulating β-ADR pathway. Interestingly, knocking down β-ADRs in
HDMECs significantly reduced cell growth that was not evident in hemSCs
(Figure 9A). These findings indicate that propranolol inhibits β-ADRs in HDMECs.
Another unique finding is that there was an increase in cell number with β1siRNA transfection under propranolol exposure when compared with control
siRNA with propranolol (Figure 9A). When β1-ADR is knocked down in HDMECs,
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there may not be sufficient levels of β1-ADR for propranolol to inhibit, relieving
the apoptotic effect observed in control transfection with propranolol.

This

highlights β-ADR-dependent mechanism of propranolol in HDMECs. In contrast,
hemSCs are not affected upon transfection with β-ADR siRNA alone (Figure 9A).
Our findings indicate that propranolol may mediate its effect through a β-ADRindependent pathway in hemSCs.
To investigate β-ADR-independent mechanism of propranolol in hemSCs, we
have performed a receptor profiling assay. All α- and β-ADRs and majority of 5HTRs in hemSCs were significantly lower compared to HDMECs (Figure 10A,
Figure 11). However, 5-HTR7 expression was almost 40 times more abundant
(Figure 11).

This was a unique finding in our study as it suggests that

propranolol may be working through this receptor pathway. Previous studies
have suggested that propranolol may bind to 5-HTRs with substantial affinity [102,
103]. There is also experimental evidence that propranolol acts as a 5-HT1A
antagonist and a 5-HT1B agonist in the rat cortex [104].

Treatment with

propranolol also inhibited basal cAMP and steroidogenesis in rat leydig cells, with
effects evident at 0.1 µM [103]. Based on the data from previous studies and our
receptor profile data, we examined whether activating or inhibiting 5-HTRs would
mimic propranolol’s effect.

We found that 5-HTR 1/7 agonist, 5-CT, can

significantly reduce hemSCs growth (Figure 12A,B).

Since 5-CT mimicked

propranolol, we tested hemSCs growth in the presence of propranolol and 5-HT
antagonist, SDZ. If propranolol’s mechanism of action is through activating 5HTRs, exposing the cells with SDZ simultaneously will normalize the effect of
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propranolol.

Indeed, this is what we have observed.

With the same

concentration of 5-CT used for SDZ and simultaneously exposing hemSCs to
propranolol, we were able to bring hemSCs growth to control levels (Figure 12A).
Therefore, 5-HT pathway may in part be involved with propranolol’s effect in
hemSCs.
Wong et al. have shown that propranolol enhances adipogenesis in hemSCs
[34]. Specifically, presence of propranolol in adipogenic media initially caused
differentiation of hemSCs but significant cell death at day 7 [34], which is the
typical in vitro time for full functional adipocyte differentiation. We reasoned that
the initial effect of propranolol might be mediated through cell cycle disruption.
To test this possibility, we treated hemSCs with mitomycin-C before exposing the
cells the adipogenic differentiation media. We noted that mitomycin-C treated
cells had significantly higher levels of C/EBPα induction (Figure 13A), suggesting
that enhanced adipogenesis in hemSCs may be related to a change in the
differentiation timeline (reduced growth and earlier differentiation).

We also

tested whether adipogenesis itself alters β-ADR expression in hemSCs, thereby
making cells more sensitive to propranolol’s direct effect through β-ADR. Indeed,
differentiation of hemSCs significantly increased the expression of all β-ADR
subtypes including β1 (29.47-fold increase as reported in our study) (Figure 13B).
IH ends its continuous developmental phase when adipocytes replace majority of
the tumour lesion.

Yu et al. first reported presence of cells with adipogenic

differentiation potential in proliferating phase IH [105]. Culturing hemSCs in the
presence of propranolol enhances adipogenesis and this may offer another

64

possible mechanism of the beneficial effects of propranolol in IH resolution.
Furthermore, continuous culture of hemSCs in adipogenic differentiation media
supplemented with propranolol causes cell death [34]. These results suggested
that propranolol treatment accelerated the dysregulated differentiation process in
hemSCs that ultimately resulted in increased apoptosis of adipocytes derived
from hemSCs [34]. It is possible that differentiation of hemSCs causes a shift in
β-ADR expression profile and an increase in β1-ADR which may induce
apoptosis.
It has been noted that propranolol causes more central nervous system-related
side effects than hydrophilic β-blockers as it can cross the blood-brain barrier [89].
Therefore, we wanted to determine whether nadolol, a hydrophilic non-selective
β-blocker, can have similar effects as propranolol in hemSCs. Nadolol may be
used as a safer alternative as it does not cross the blood-brain barrier and have
little myocardial effect, unlike propranolol [106, 107].

Interestingly, hemSCs

growth was significantly reduced at 25 and 100 µM nadolol.

A significant

reduction of HDMECs was also evident but only at 100 µM nadolol treatment
(Figure 15). Clinically, it has been shown that nadolol effects are more favorable
compared to propranolol-use after 24 weeks with similar doses administered
[108]. These findings suggest that other β-blockers can offer another therapeutic
option; however, further studies need to be performed to understand the
mechanism of how these various β-blockers may be regressing IH.
Previous studies have observed that propranolol can act as a membrane
stabilizing agent [90, 109].

To determine whether propranolol’s effect was
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mediated through receptors expressed on the cell surface or indirectly by
stabilizing the cell membrane, we have treated the cells with quinidine, a
membrane stabilizing agent that can block sodium and potassium channels.
Interestingly, it has been noted that 100 µM quinidine can inhibit proliferation and
induce apoptosis by increasing caspase-3 and -9 in human glioma U86-MG cells
[110]. Surprisingly, at 1 µM quinidine, there was a significant increase in live
hemSCs number and only at 100 µM quinidine did it significantly decrease
hemSCs growth compared with control (Figure 16). This profile is identical to the
one seen with propranolol at 25 and 100 µM after 72 hours (Figure 3B).
Surprisingly, HDMECs were unaffected at all concentrations of quinidine used
when compared with control (Figure 16).

Our data suggest that the cellular

components of hemSCs and HDMECs are quite different, and it would be
important to investigate whether the decrease in hemSCs upon 100 µM quinidine
is due to apoptosis and/or cell cycle arrest. Furthermore, our findings highlight
the importance of understanding the cellular receptor components to target
hemSCs.

Our study demonstrates that although hemSCs are responsive to

propranolol by inhibiting cellular growth and inducing anti-apoptotic genes, the
mechanism by which propranolol mediates its effects in hemSCs are through βADR-independent effects.
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4.1.1

Concluding remarks

Propranolol has shown promising effects in IH resolution and many studies have
sought to understand the mechanism of propranolol’s effective treatment.
Although the mechanism of action is not fully understood, our study represents
an important step towards understanding propranolol’s action.

Our findings

provide novel insight into the possibility that propranolol may affect hemangiomainitiating cells (hemSCs) through a β-adrenergic receptor-independent pathway,
potentially involving 5-HTRs and membrane stabilization.

Identification of

cytoplasmic regulatory proteins in hemSCs that interact with β-ADR and 5-HTRs
may represent an attractive future research area for the development of cell-type
specific therapies.
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4.2

Future Direction

Although propranolol is efficacious, there is quite a bit of knowledge gap. There
are possibilities that need to be explored: 1) involvement of receptor dimerization
and α-ADR signaling, 2) involvement of 5-HT signaling, and 3) role of membrane
stabilizing effects.
Although data is limited, propranolol does stereoselectively bind and inhibit αADR in the heart [111]. Immunoprecipitation studies also show that β1-ADR and
α2-ADR heterodimerize when co-expressed [112]. This interaction changes the
pharmacological properties of β1-ADR as shown by ligand binding assays. β1and β2- ADR have also been shown to heterodimerize [113, 114].

These

findings suggest that the profile of ADR receptors may have functional cellular
consequence and represents an area of significant future research interest. In
addition, our data suggest that β1-ADR is the key receptor that mediates
apoptosis in HDMECs, and since hemSCs β1-ADR level is hardly detectable,
apoptosis is not evident in this cell type. Therefore, it would be interesting to
investigate whether overexpression of β1-ADR in hemSCs would induce
apoptosis upon propranolol exposure.
Moreover, a number of pressing questions remain. For example, is propranolol
selective to IH vessels? Based on recent findings in endothelial cells (normal vs
IH-derived) and our own findings in hemSCs, this seems unlikely. Alternatively,
the effectiveness of propranolol in IHs may be a function of increased levels that
are sustained in the capillary mass of IHs.
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Lastly, are there better alternatives to propranolol? Further studies need to be
conducted to determine whether activation of 5-HTRs can induce apoptosis
and/or reduce anti-apoptotic genes. This would allow for alternative treatments
to target 5-HTRs rather than β-ADRs as it is highly expressed in hemSCs. Also,
based on our data, nadolol has similar growth effect in hemangioma-derived
stem cells to propranolol. Therefore, further studies are needed to determine
whether similar anti-apoptotic gene profile is induced, and whether it can induce
apoptosis in hemSCs to prevent recurrence of hemangiomas. Moreover, it would
be interesting to observe the receptor profile after nadolol exposure and compare
to the changes of propranolol’s receptor profile.
These studies are underway in our laboratory and the findings may enhance our
understanding of the mechanism of therapeutic action of propranolol and may
provide more effective treatment options.
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